Compare LQDA & STWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | STWD |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.2B |
| IPO Year | 2020 | 2009 |
| Metric | LQDA | STWD |
|---|---|---|
| Price | $78.03 | $16.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $41.00 | $20.00 |
| AVG Volume (30 Days) | 2.4M | ★ 3.4M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 10.64% |
| EPS Growth | ★ 51.81 | 4.55 |
| EPS | ★ 0.52 | 0.13 |
| Revenue | $158,320,000.00 | ★ $1,844,289,000.00 |
| Revenue This Year | $278.87 | $283.44 |
| Revenue Next Year | $57.13 | $17.66 |
| P/E Ratio | $147.92 | ★ $127.85 |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $11.85 | $16.58 |
| 52 Week High | $78.25 | $20.99 |
| Indicator | LQDA | STWD |
|---|---|---|
| Relative Strength Index (RSI) | 75.44 | 43.06 |
| Support Level | $31.23 | N/A |
| Resistance Level | N/A | $18.59 |
| Average True Range (ATR) | 4.14 | 0.26 |
| MACD | 0.40 | 0.00 |
| Stochastic Oscillator | 91.55 | 26.76 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Starwood Property Trust Inc is a real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans, commercial mortgage-backed securities, and other real estate investments in the U.S., Australia, and Europe. The company has four reportable business segments: Commercial and Residential Lending, Infrastructure Lending, Property, and Investing and Servicing. The majority of its revenue is generated from the Commercial and Residential Lending segment, which engages mainly in originating, acquiring, financing, and managing commercial first mortgages, non-agency residential mortgages (residential loans), commercial mortgage-backed securities (CMBS), residential mortgage-backed securities (RMBS), and other real estate and related debt investments.